&w=3840&q=100)
Institutional buyers drive demand for Anthem Biosciences IPO; GMP up 26%
Among the individual categories, NIIs have oversubscribed the category reserved for them by 27.08 times, followed by QIBs at 11.86 times, and retail investors at 3.80 imes.
Anthem Biosciences IPO grey market premium (GMP) today
The favourable sentiments were seen in the grey markets too, where the company's unlisted shares were exchanging hands at around ₹720 apiece, reflecting a grey market premium (GMP) of ₹150 per share or approximately 26.32 per cent above the upper end of the IPO price band of ₹570 apiece, according to the sources tracking grey market activities.
Anthem Biosciences IPO review
Analysts at Anand Rathi Research have assigned a subscribe rating to the issue, citing the company's potential to continue to grow its revenue and profitability ratios compared to its peers. Those at SBI Securities have recommended the investors to subscribe to the public issue for the long-term perspective, citing that the IPO is fairly priced while comparing with peers, along with a superior return and margin profile.
Anthem Biosciences IPO details
The ₹3,395.00 crore public issue of Anthem Biosciences comprises an entirely offer for sale (OFS) with promoters and shareholders divesting 59.6 million equity shares. The public issue is being offered in a price band of ₹540-570 per share, with a lot size of 26 shares. A retail investor can bid for a minimum of 1 lot or 26 and in multiples thereof, with a minimum investment of ₹14,820.
As the subscription window closed today, the basis of allotment of Anthem Biosciences IPO shares is expected to be finalised on July 17, with shares credited to successful applicants' demat accounts on July 18.
Anthem Biosciences shares are scheduled to list on the NSE and BSE tentatively on July 21, 2025.
Kfin Technologies is acting as the registrar to the issue, while JM Financial is serving as the sole book-running lead manager.
About Anthem Biosciences
Anthem Biosciences is an innovation-led CRDMO (Contract Research Development and Manufacturing Organization) in India, offering end-to-end services across drug discovery, development, and manufacturing for both New Chemical Entity (NCE) and New Biological Entity (NBE). The company is among a select group of Indian players with integrated capabilities spanning New Chemical Entities (NCEs) and New Biological Entities (NBEs) across the drug discovery, development, and commercial manufacturing value chain.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
a minute ago
- Business Standard
Tilaknagar zooms 28% in 1 week. What's driving alcoholic beverage stock?
Tilaknagar Industries share price today Shares of Tilaknagar Industries surged 10 per cent to ₹436.30 on the BSE in Monday's intra-day trade amid heavy volumes after the company announced its fund raising plan. The stock was trading close to its 52-week high of ₹457.30 touched on January 3, 2025. In the past one week, the stock price of the Indian-Made Foreign Liquor (IMFL) manufacturer has zoomed 28 per cent, as compared to 0.30 per cent decline in the BSE Sensex. At 10:28 AM; Tilaknagar Industries was quoting 8.6 per cent higher at ₹431, as against 0.39 per cent rise in the benchmark index. The average trading volumes on the counter jumped over three-fold. A combined 8.64 million equity shares representing 4.5 per cent of total equity of Tilaknagar Industries changed hands on the NSE and BSE. Tilaknagar - Fund raising plan Tilaknagar Industries on Saturday, July 19, 2025 informed that a meeting of the board of directors of the company will be held on Wednesday, July 23, 2025, inter alia to consider the fund raising plan. In a regulatory filing, the liquor maker said the board will deliberate on issuing equity shares or a mix of financial instruments, including debentures, warrants, preference shares, or foreign currency convertible bonds. The raise could be executed through multiple channels like public offer, rights issue, preferential issue, qualified institutional placement (QIP), or private placement, depending on market conditions and regulatory permissions. Favourable Bombay High Court ruling - Tilaknagar Industries The Bombay High Court has ruled in favour of Tilaknagar Industries, restraining Allied Blenders & Distillers (ABDL) from launching the 'Mansion House' and 'Savoy Club' spirit brands across India. These orders have not only upheld the ownership and proprietary rights of Tilaknagar Industries under the trademarks Mansion House & Savoy Club, while allowing Tilaknagar Industries to continue its uninterrupted, exclusive use and sale of the brands Mansion House & Savoy Club, but have also restrained other entities such as UTO Nederland B V (UTO) & ABDL from using and/or launching the brand Mansion House & Savoy Club in all of India by protecting exclusive usage rights in favour of Tilaknagar Industries. ABDL has notified the exchange that they are exploring options to challenge the order in higher court and cannot ascertain any material financial impact at the moment. Tilaknagar - Management commentary post Q4 results The company's January to March 2025 quarter (Q4FY25) saw a very strong close to the year; with high volume and value-led growth. Quarterly growth was driven by resumption of strong performance in largest state of Andhra Pradesh (AP), both on year-on-year (YoY) and quarter-on-quarter (QoQ) terms. The Route to Market (RTM) change in AP is completed, and the management expects the company's performance in the state to continue its growth trajectory, in-line with the industry. AP has been well supported by the company's other Southern states, each of which have seen market share improvements. About Tilaknagar Industries Tilaknagar Industries (TI) is one of India's leading alcoholic beverage companies. The company has over the years transformed in to a major player in the India Made Foreign Liquor (IMFL) industry having a manufacturing footprint of 19 units across 12 states. TI's brand portfolio straddles multiple categories, featuring two 'Millionaire' brandy brands - Mansion House and Courrier Napoleon- along with a strong presence in whisky, rum, and gin through Mansion House Whisky, Madiraa Rum and Blue Lagoon Gin. Recently, TI has expanded into the luxury segment with Monarch Legacy Edition Brandy.
&w=3840&q=100)
Business Standard
a minute ago
- Business Standard
Brokerages remain divided on RBL Bank after Q1 result; check recommendation
RBL Bank shares slipped 3.2 per cent, logging an intraday low at ₹254.7 per share on BSE. The selling pressure on the counter came after the company posted Q1 results. At 11:19 AM, RBL Bank share price was trading 1.65 per cent lower at ₹258.8 per share on the BSE. In comparison, the BSE Sensex was up 0.48 per cent at 82,148.37. The company's market capitalisation stood at ₹15,765.65 crore. The 52-week high of the stock was at ₹272.9 per share, and the 52-week low of the stock was at ₹146 per share. What should investors do with RBL Bank shares post Q1FY26 results? Motilal Oswal has maintained a 'Buy' with a target price of ₹290 per share. According to the brokerage, the bank reported a beat on earnings, with margins sharply moderating due to the repo rate cuts. Deposits grew 2 per cent quarter-on-quarter (Q-o-Q), with the current account savings account (CASA) ratio moderating to 32.5 per cent. Advances also increased 2 per cent Q-o-Q, with the bank expecting it to grow in the mid-teens, with a mid-to-high teen growth in wholesale advances. Post the results, Motilal Oswal fine-tuned its earnings per share (EPS) estimates and projected an FY27E return on asset/ return on equity (RoA/RoE) of 1.07 per cent/11.4 per cent. Incred Equities has also iterated 'Add' with an upward revision in target to ₹290 per share from ₹260. The brokerage believes that moderating the microfinance institutions (MFI) Special Mention Account (SMA) book is comforting and improves visibility of 200 basis points (bp) credit costs for FY26F. However, ICICI Securities has downgraded RBL Bank to 'Hold' from 'Add' with a revised target to ₹250 from ₹210. "RBL Bank reported a weak Q1 performance, with a sharp 40 bps Q-o-Q decline in net interest margin (NIM), double-digit drop in net interest income (NII), and no improvement in slippages (new bad loans)," the brokerage note read. Check List of Q1 results today RBL Bank Q1 results The bank posted a 46 per cent year-on-year (Y-o-Y) decline in its net profit to ₹200 crore for the quarter ended June 30, 2025, compared to ₹371.5 crore a year ago. The Net Interest Income (NII) of the lender fell 13 per cent Y-o-Y to ₹1,481 crore from ₹1,700 crore, and declined 5 per cent sequentially from ₹1,563 crore in the March 2025 quarter. Net Interest Margin (NIM) for the quarter stood at 4.50 per cent, as compared to 4.89 per cent in Q4FY25, and 5.67 per cent in the year-ago period. Other income of the bank rose by 33 per cent to ₹1,069 crore during the quarter, against ₹805 crore in the same period last year. In Q4FY25, other income stood at ₹1,000 crore.
News18
24 minutes ago
- News18
Anthem Biosciences stock jumps nearly 27 pc in market debut trade
New Delhi, Jul 21 (PTI) Shares of Anthem Biosciences Ltd listed with a premium of nearly 27 per cent against the issue price of Rs 570 on Monday. The company's stock started trading at Rs 723.10, surging 26.85 per cent from the issue price on the BSE. Later, it jumped 31 per cent to Rs 746.70. At the NSE, the stock listed at Rs 723.05, rallying 26.85 per cent. The company's market valuation stood at Rs 40,716.73 crore. The Rs 3,395-crore initial public offer of Anthem Biosciences Ltd got subscribed 63.86 times on the closing day of bidding on Wednesday last week, driven by overwhelming participation from institutional buyers. The initial share sale had a price band of 540-570 per share. Since the IPO was entirely an Offer For Sale (OFS), the company will not receive any funds from the issue, and the proceeds will go to the selling shareholders. It also manufactures and sells complex, specialised fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. PTI SUM SUM DR DR view comments First Published: July 21, 2025, 11:30 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
